SARS-CoV-2 (n = 1243) | Influenza (n = 775) | RSV (n = 242) | |
---|---|---|---|
Patient characteristics | |||
Male sex, n (%) | 805 (65) | 403 (52) | 113 (47) |
Age, median (IQR), years | 62 (52–73) | 69 (54–79) | 71 (61–81) |
≥ 65, n (%) | 520 (42) | 442 (57) | 170 (70) |
CCI, median (IQR), points | 1 (0–2) | 1 (0–3) | 2 (1–3) |
0–1, n (%) | 871 (70) | 406 (52) | 101 (42) |
2–4, n (%) | 291 (23) | 279 (36) | 103 (43) |
≥ 5, n (%) | 81 (7) | 90 (12) | 38 (16) |
Specific comorbiditiesa | |||
Diabetes mellitus, n (%) | 338 (27) | 139 (18) | 47 (19) |
Hypertension, n (%) | 565 (45) | 265 (34) | 95 (39) |
Chronic cardiac disease, n (%) | 375 (30) | 266 (34) | 101 (42) |
Chronic respiratory disease, n (%) | 444 (36) | 233 (30) | 82 (34) |
Chronic kidney disease, n (%) | 86 (7) | 65 (8) | 29 (12) |
Malignancy, n (%) | 110 (9) | 167 (22) | 75 (31) |
Immunosuppression, n (%) | 192 (15) | 236 (30) | 100 (41) |
Any of the comorbidities above, n (%) | 911 (73) | 560 (72) | 198 (82) |
Admission characteristics | |||
Respiratory rate ≥ 30 breaths/min, n (%) | 393 (32) | 262 (34) | 75 (31) |
Systolic blood pressure < 90 mmHg or diastolic blood pressure ≤ 60 mmHg, n (%) | 340 (28) | 346 (45) | 99 (42) |
Non-alert, n (%) | 117 (10) | 55 (9) | 15 (8) |
Antibiotic administered at admission (outside the ICU), n (%) | 407 (33) | 650 (84) | 213 (88) |
Third-generation cephalosporins, n (%) | 311 (25) | 436 (56) | 130 (54) |
Penicillins, n (%) | 73 (6) | 246 (32) | 83 (34) |
Fluoroquinolones, n (%) | 14 (1) | 72 (9) | 26 (11) |
Clinical outcomes | |||
LOS, median (days) | 8 (5–15) | 5 (3–8) | 5 (3–9) |
ICU-admission, n (%) | 313 (25) | 131 (17) | 38 (16) |
30-day mortality, n (%) | 142 (11) | 55 (7) | 16 (7) |